TMU Research Center of Cancer Translational Medicine

Yen-Shen Lu M.D., Ph.D.

Department of Oncology ,National Taiwan University Hospital No. 7, Chung Shan South Road, Taipei, Taiwan, 100

Contact Information

AddressDepartment of Oncology National Taiwan University Hospital No. 7, Chung Shan South Road, Taipei, Taiwan, 100
Tel886-2-23123456 ext 71673
Fax886-2-23711174
E-mailyslu@ntu.edu.tw

Education

1985-1992M.D., Chinese Medical College of Medicine
1998-2006Ph.D., Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University

PROFESSIONAL TRAINING

HOSPITAL APPOINTMENTS

2007-2008Adjunct Assistant Professor, Department of Internal Medicine, National Taiwan University College of Medicine
2008-2014Clinical Assistant Professor, Department of Internal Medicine, National Taiwan University College of Medicine
2014-2018Clinical Associate Professor, Department of Internal Medicine, National Taiwan University College of Medicine
2018-2024Clinical Professor Clinical Professor, Department of Internal Medicine, National Taiwan University College of Medicine
2024-presentProfessor, Graduate Institute of Oncology, National Taiwan University College of Medicine

LICENSURE and CERTIFICATION

1992-presentChinese Medical License, #021928
1997-presentChinese Board of Internal Medicine, #004509
1998-presentChinese Board of Medical Oncology, #870003
2006-presentChinese Board of Mammary Medicine, #0415

MEMBERSHIPS

1996-presentTaiwan Society of Internal Medicine
1998-presentThe Chinese Oncology Society
2001-presentAmerican Association of Cancer Research
2004-presentThe Breast Cancer Society of Taiwan
2013-presentAmerican Society of Clinical Oncology

AWARD

  • Scholar in Training Award of 92th Annual Meeting of AACR in 2001
  • Chien-Tien Hsu’s Outstanding Cancer Research Award 2019
  • Mistry of Science and Technology Outstanding Research Award 2020
  • National Taiwan University Hospital Outstanding Research Award 2020
  • National Taiwan University Outstanding Research Award 2020
  •  Far Eastern Y.Z.Hsu Foundation Scientific award 2024

CLINICAL TRIALS EXPERIENCE

  • Member of Scientific Committee, TRIO (Translational Research in Oncology)2019-presnet
  • Pass the US FDA inspection as a principal investigator in 2019

Study initiator and protocol writer of investigator initiated trial

  1. A randomized, open-label, parallel-group study comparing the immune modulation effect of ribociclib, palbociclib, and abemaciclib in early ER+/HER2- breast cancer.
  2. A randomized, pick-the-winner, phase II study for premenopausal metastatic or locally advanced breast cancer patients: capivasertib, goserelin, fulvestrant with or without durvalumab (MEDI  4736), versus goserelin, fulvestrant, and durvalumab (MEDI4736), versus  goserelin/ fulvestrant.
  3. A Pilot Study of Pembrolizumab and Exemestane/ Leuprolide in Premenopausal Hormone Receptor Positive/ HER2 Negative Locally Advanced or Metastatic Breast Cancer
  4. The landscape of ESR1 mutations in Asian estrogen receptor-positive metastatic breast cancer patients detected by liquid biopsy and impact on hormonal therapy -based treatments
  5. Randomized phase II study of induction Bevacizumab, Etoposide and Cisplatin followed by whole brain radiotherapy versus radiotherapy alone in breast cancer with untreated brain metastases
  6. A phase II randomized study of the combination of Tamoxifen plus Goserelin Acetate with BYL719 or Buparlisib (BKM120) in premenopausal patients with hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer
  7. A phase II study of Bevacizumab with Etoposide and Cisplatin in breast cancer patients with brain and/or leptomeningeal metastasis
  8. A randomized phase III study of Docetaxel/Epirubicin versus tailored regimens as neoadjuvant chemotherapy for stage II/III breast cancer with tumor size more than 2 cm
  9. A phase I/II study of Lapatinib plus oral Vinorelbine for patients with ErbB2 positive metastatic breast cancer
  10. Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer

Chair or co-chair of steering committee of International clinical trials

  • A phase Ib study of the combination of Tamoxifen plus Goserelin Acetate with BYL719 or Buparlisib (BKM120) in premenopausal patients with hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (BYOND)
  • A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer (MONALEESA-7)
  • A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer (RIGHT Choice)

SCI PUBLICATIONS

  1. Interaction of base excision repair gene polymorphism and estrogen-DNA adducts in breast cancer risk among East Asian women. Chen HW, Kuo WH, Lu YS, Chen IC, Hu FC, Wang MY, Zahid M, Rogan EG, Cheng AL, Lin CH. Breast Cancer Res Treat. 2024 Nov;208(2):283-292.
  2. SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials. Borrego MR, Lu YS, Reyes-Cosmelli F, Park YH, Yamashita T, Chiu J, Airoldi M, Turner N, Fein L, Ghaznawi F, Singh J, Pantoja K, Schnell C, Akdere M, Chia S. Breast Cancer Res Treat. 2024 Nov;208(1):111-121.
  3. Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials. André F, Solovieff N, Su F, Bardia A, Neven P, Yap YS, Tripathy D, Lu YS, Slamon D, Chia S, Joshi M, Chakravartty A, Lteif A, Taran T, Arteaga CL. Ann Oncol. 2024 Sep 21:S0923-7534(24)04018-3.
  4. Characteristics and transcriptional regulators of spontaneous epithelial-mesenchymal transition in genetically unperturbed patient-derived non-spindled breast carcinoma. Lien HC, Yu HC, Yu WH, Lin SF, Chen TW, Chen IC, Hsiao LP, Yeh LC, Li YC, Lo C, Lu YS. Breast Cancer Res. 2024 Sep 10;26(1):130.
  5. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, Laurentiis M, Jañez NM, Adamo B, Lee KS, Jung KH, Rubovszky G, Tseng LM, Lu YS, Yuan Y, Maxwell MJ, Haddad V, Khan SS, Rugo HS, Pistilli B. Future Oncol. 2024 Mar;20(8):423-436.
  6. Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Yamashita T, Sohn JH, Tokunaga E, Niikura N, Park YH, Lee KS, Chae YS, Xu B, Wang X, Im SA, Li W, Lu YS, Aguilar CO, Nishijima S, Nishiyama Y, Sugihara M, Modi S, Tsurutani J. Breast Cancer. 2024 Sep;31(5):858-868.
  7. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B; TROPION-Breast01 Investigators. J Clin Oncol. 2024 Sep 12:JCO2400920.
  8. Survival outcomes of young-age female patients with early breast cancer: an international multicenter cohort study. Kim J, Kim J, Seo KH, Lee KH, Park YH, Lin CH, Lu YS, Ueno T, Yap YS, Wong FY, Tan VKM, Lim GH, Tan SM, Yeo W, Liu Q, Leung R, Naito Y, Li H, Lee HB, Han W, Im SA; Asian Breast Cancer Cooperative Group. ESMO Open. 2024 Oct 15;9(11):103732.
  9. A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. Noguchi E, Yamanaka T, Mukai H, Yamamoto N, Chung CF, Lu YS, Chang DY, Sohn J, Kim GM, Lee KH, Lee SC, Iwasa T, Iwata H, Watanabe K, Jung KH, Tanabe Y, Kang SY, Yasojima H, Aogi K, Tokunaga E, Sim SH, Yap YS, Matsumoto K, Tseng LM, Umeyama Y, Sudo K, Kojima Y, Hata T, Kuchiba A, Shibata T, Nakamura K, Fujiwara Y, Tamura K, Yonemori K. NPJ Breast Cancer. 2024 Aug 22;10(1):76.
  10. Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysis. Yang MH, Huang CS, Chang DY, Hu FC, Huang SM, Huang PH, Chen IC, Chen TW, Lin CH, Lu YS*. Cancer Med. 2024 Jul;13(14):e70005. doi: 10.1002/cam4.70005. *correspondence.
  11. Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study. Tan RYC, Ong WS, Lee KH, Park S, Iqbal J, Park YH, Lee JE, Yu JH, Lin CH, Lu YS, Ono M, Ueno T, Naito Y, Onishi T, Lim GH, Tan SM, Lee HB, Koh J, Han W, Im SA, Tan VKM, Phyu N, Wong FY, Tan PH, Yap YS. J Natl Compr Canc Netw. 2024 May 14;22(2D):e237121.
  12. In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment. Lien HC, Lo C, Lee YH, Lin PH, Wang MY, Kuo WH, Tsai LW, Lu YS, Hu HW, Li YC, Huang CS. Breast Cancer Res. 2024 Jun 12;26(1):100.
  13. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer. Park KH, Loibl S, Sohn J, Park YH, Jiang Z, Tadjoedin H, Nag S, Saji S, Md Yusof M, Villegas EMB, Lim EH, Lu YS, Ithimakin S, Tseng LM, Dejthevaporn T, Chen TW, Lee SC, Galvez C, Malwinder S, Kogawa T, Bajpai J, Brahma B, Wang S, Curigliano G, Yoshino T, Kim SB, Pentheroudakis G, Im SA, Andre F, Ahn JB, Harbeck N. ESMO Open. 2024 May;9(5):102974.
  14. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer. Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, Laurentiis M, Jañez NM, Adamo B, Lee KS, Jung KH, Rubovszky G, Tseng LM, Lu YS, Yuan Y, Maxwell MJ, Haddad V, Khan SS, Rugo HS, Pistilli B. Future Oncol. 2024 Mar;20(8):423-436.
  15. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Lu YS, Mahidin EIBM, Azim H, Eralp Y, Yap YS, Im SA, Rihani J, Gokmen E, El Bastawisy A, Karadurmus N, Lim YN, Lim CS, Duc LT, Chung WP, Babu KG, Penkov K, Bowles J, Alfaro TD, Wu J, Gao M, Slimane K, El Saghir NS. 2024 Aug 10;42(23):2812-2821.
  16. Genetic Insights into Carbohydrate Sulfotransferase 8 and Its Impact on The Immunotherapy Efficacy of Cancer. Chou WC, Chen WT, Kuo CT, Chang YM, Lu YS, Li CW, Hung MC, Shen CY. Cell Reports, 2024;43(1):113641.
  17. miR-622 Increases miR-30a Expression through Inhibition of Hypoxia-Inducible Factor 1α to Improve Metastasis and Chemoresistance in Human Invasive Cheng CW, Liu YF, Liao WL, Chen PM, Hung YT, Lee HJ, Cheng YC, Wu PE, Lu YS, Shen CY. Breast Cancer Cells. Cancers, 2024;16:657.
  18. Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial. JAMA Oncology. Tom Wei-Wu Chen, Ming-Shen Dai, Ling-Ming Tseng, Shin-Cheh Chen, Tsu-Yi Chao, Ta-Chung Chao, Yuan-Ching Chang, Chang-Fang Chiu, Chien-Ting Liu, Ching-Hung Lin, Chun-Yu Liu, Ya-Fang Chen, Dwan-Ying Chang, Jyh-Cherng Yu, Kun-Ming Rau, Yao-Yu Hsieh, Shih-Che Shen, Shu-Min Huang, Ann-Lii Cheng, Yen-Shen Lu*, JAMA Oncol 2024 Mar 1;10(3):325-334. *Correspondence.
  19. A novel computer-assisted tool for 3D imaging of programmed death-ligand 1 expression in immunofluorescence-stained and optically cleared breast cancer specimens. Lee YH, Huang CY, Hsieh YH, Yang CH, Hung YL, Chen YA, Lin YC, Lin CH, Lee JH, Wang MY, Kuo WH, Lin YY, Lu YS*. BMC Cancer. 2024 Jan 24;24(1):121. *Correspondence.  
  20. Estrogen-DNA Adducts and Breast Cancer Risk in Premenopausal Asian Women. Lin CH, Zahid M, Kuo WH, Hu FC, Wang MY, Chen IC, Beseler CL, Mondal B, Lu YS, Rogan EG, Cheng AL. Cancer Prev Res (Phila). 2023 Mar 1;16(3):153-161. doi: 10.1158/1940-6207.CAPR-22-0415. PMID: 36517463
  21. Disparity in survival benefits of pembrolizumab between Asian and non-Asian patients with advanced cancers: A systematic review and meta-regression analysis. Peng SH, Lin CH, Chen IC, Shen YC, Chang DY, Chen TW, Huang SM, Hu FC, Lu YS.* Cancer Med. 2023 Oct;12(19):20035-20051. * Correspondence.
  22. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. André F, Su F, Solovieff N, Hortobagyi G, Chia S, Neven P, Bardia A, Tripathy D, Lu YS, Lteif A, Taran T, Babbar N, Slamon D, Arteaga CL. Ann Oncol. 2023 Nov;34(11):1003-1014.
  23. Lifestyle Factors and Energy Intakes with Risks of Breast Cancer among Pre- and Post- Menopausal Women in Taiwan. Huang MC, Huang TT, Feng HC, Chen IC, Chang CI, Wang TN, Kuo WH, Wang MY, Tsai LW, Li SY, Huang CS, Lu YS, Lin CH. Nutrients. 2023 Sep 7;15(18):3900.
  24. Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study. Dai MS, Chao TC, Chiu CF, Lu YS, Shiah HS, Jackson CGCA, Hung N, Zhi J, Cutler DL, Kwan R, Kramer D, Chan WK, Qin A, Tseng KC, Hung CT, Chao TY. Ther Adv Med Oncol. 2023 Jul 21;15:17588359231183680.
  25. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. N Engl J Med. 2023 Jun 1;388(22):2058-2070.
  26. The Application of 18F-FES PET in Clinical Cancer Care: A Systematic Review. Huang YT, Chen TW, Chen LY, Huang YY, Lu YS*. Clin Nucl Med.  2023 Sep 1;48(9):785-795. *Correspondence
  27. Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma. Lin ZZ, Hu MC, Hsu C, Wu YM, Lu YS, Ho JA, Yeh SH, Chen PJ, Cheng AL. Cancer Lett. 2023 Mar 1;556:216063.
  28. Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma. Lien HC, Hsu CL, Lu YS, Chen TW, Chen IC, Li YC, Huang CS, Cheng AL, Lin CH. Breast Cancer Res. 2023 Jan 27;25(1):11.
  29. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer. Chen TW, Hsiao W, Dai MS, Lin CH, Chang DY, Chen IC, Wang MY, Chang SH, Huang SM, Cheng AL, Wu KW, Tan KT, Lu YS. Breast Cancer Res Treat. 2023 Jun 21. 2023 Oct;201(3):377-385.
  30. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690.
  31. Estrogen-DNA Adducts and Breast Cancer Risk in Premenopausal Asian Women. Lin CH, Zahid M, Kuo WH, Hu FC, Wang MY, Chen IC, Beseler CL, Mondal B, Lu YS, Rogan EG, Cheng AL. Cancer Prev Res (Phila). 2023 Mar 1;16(3):153-161.
  32. Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients. Lin PH, Chen SC, Tseng LM, Chang KJ, Huang AC, Cheng KC, Yang K, Wu HC, Chao TY, Chang YC, Lin PC, Kuo WH, Kuo WL, Lin CH, Chen HM, Yeh DC, Liu LC, Liu CY, Wang MY, Lo C, Lu YS, Huang CS. Breast Cancer Res Treat. 2022 Apr;192(3):629-637. doi: 10.1007/s10549-021-06446-7. Epub 2022 Feb 3. PMID: 35113257
  33. Clinical Outcomes of Metastatic Breast Cancer in Patients Having Imaging Liver Pseudocirrhosis with or without Evident Varices. Ma WL, Chang DY, Lin CH, Liu KL, Liang PC, Lien HC, Hu CC, Huang LY, Yeh YC, Lu YS. Oncologist. 2022 Dec 9;27(12):1008-1015.
  34. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. Tan RSYC, Ong WS, Lee KH, Lim AH, Park S, Park YH, Lin CH, Lu YS, Ono M, Ueno T, Naito Y, Onishi T, Lim GH, Tan SM, Lee HB, Ryu HS, Han W, Tan VKM, Wong FY, Im SA, Tan PH, Chan JY, Yap YS. BMC Med. 2022 Mar 17;20(1):105.
  35. Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients. Lin PH, Chen SC, Tseng LM, Chang KJ, Huang AC, Cheng KC, Yang K, Wu HC, Chao TY, Chang YC, Lin PC, Kuo WH, Kuo WL, Lin CH, Chen HM, Yeh DC, Liu LC, Liu CY, Wang MY, Lo C, Lu YS, Huang CS. Breast Cancer Res Treat. 2022 Apr;192(3):629-637.
  36. Updated Overall Survival of Ribociclib Plus Endocrine Therapy vs Endocrine Therapy Alone in Pre- and Perimenopausal Patients With HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Yen-Sen Lu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Fatima Cardoso, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K. Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi El-Saghir, Ruth O’Regan, Claudia Gasch, Nadia Solovieff, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yan Ji and Debu Tripathy. Clin Cancer Res 2022 Mar 1;28(5):851-859.
  37. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. Kuemmel S, Campone M, Loirat D, Lopez RL, Beck JT, De Laurentiis M, Im SA, Kim SB, Kwong A, Steger GG, Adelantado EZ, Duhoux FP, Greil R, Kuter I, Lu YS, Tibau A, Özgüroğlu M, Scholz CW, Singer CF, Vega E, Wimberger P, Zamagni C, Couillebault XM, Fan L, Guerreiro N, Mataraza J, Sand-Dejmek J, Chan A. Clin Cancer Res. 2022 Jan 1;28(1):106-115.
  38. An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. Lu YS, Yeo W, Yap YS, Park YH, Tamura K, Li H, Cheng R. Target Oncol. 2021 Nov;16(6):701-741.
  39. Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer. Fasching PA, Delea TE, Lu YS, De Boer R, Hurvitz SA, Moynahan A, Chandiwana D, Lanoue B, Hu H, Thuerigen A, O’Shaughnessy J. Cancer Manag Res. 2021 Nov 1;13:8179-8189. doi: 10.2147/CMAR.S325043. eCollection 2021.
  40. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. Dai MS, Feng YH, Chen SW, Masuda N, Yau T, Chen ST, Lu YS, Yap YS, Ang PCS, Chu SC, Kwong A, Lee KS, Ow S, Kim SB, Lin J, Chung HC, Ngan R, Kok VC, Rau KM, Sangai T, Ng TY, Tseng LM, Bryce R, Bebchuk J, Chen MC, Hou MF. Breast Cancer Res Treat. 2021 Oct;189(3):665-676.
  41. Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. Bardia A, Su F, Solovieff N, Im SA, Sohn J, Lee KS, Campos-Gomez S, Jung KH, Colleoni M, Vázquez RV, Franke F, Hurvitz S, Harbeck N, Chow L, Taran T, Rodriguez Lorenc K, Babbar N, Tripathy D, Lu YS. JCO Precis Oncol. 2021 Sep 1;5:PO.20.00445. doi: 10.1200/PO.20.00445. eCollection 2021.
  42. Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients. Chen IC, Hu FC, Lin CH, Huang SM, Chang DY, Cheng AL, Lu YS. Breast. 2021 Oct;59:211-220. 
  43. Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer. Fasching PA, Delea TE, Lu YS, De Boer R, Hurvitz SA, Moynahan A, Chandiwana D, Lanoue B, Hu H, Thuerigen A, O’Shaughnessy J. Cancer Manag Res. 2021 Nov 1;13:8179-8189.
  44. Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women. Lu YS, Wong A, Kim HJ. Front Oncol. 2021 Sep 14;11:700722.
  45. High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia. Lin CH, Huang RY, Lu TP, Kuo KT, Lo KY, Chen CH, Chen IC, Lu YS, Chuang EY, Thiery JP, Huang CS, Cheng AL. NPJ Breast Cancer. 2021 Jul 5;7(1):88.
  46. Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives. Chang DY, Ma WL, Lu YS*. Ther Clin Risk Manag. 2021 Mar 5;17:193-207. Corresponding author
  47. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. Schmid P, Sablin MP, Bergh J, Im SA, Lu YS, Martínez N, Neven P, Lee KS, Morales S, Pérez-Fidalgo JA, Adamson D, Gonçalves A, Prat A, Jerusalem G, Schlieker L, Espadero RM, Bogenrieder T, Huang DC, Crown J, Cortés J. Breast Cancer Res. 2021 Jan 15;23(1):8.
  48. Regulatory and Operational Challenges in Conducting Asian International Academic Trial for Expanding the Indications of Cancer Drugs. Hata T, Nakamura K, Yonemori K, Noguchi E, Watanabe M, Sohn J, Lu YS, Yap YS, Tamura K, Fujiwara Y. Clin Transl Sci. 2021 May;14(3):1015-1025.
  49. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Pápai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte PF, Iwata H, Rugo HS. Ann Oncol. 2021 Feb;32(2):208-217.
  50. Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components. Lien HC, Lee YH, Chen IC, Lin CH, Chen TW, Lu YT, Lu YS*. Virchows Arch. 2021 Apr;478(4):669-678. Corresponding author
  51. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial. Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A; NALA Investigators. J Clin Oncol. 2020 Sep 20;38(27):3138-3149.
  52. A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women. Tsai MS, Chang SH, Kuo WH, Kuo CH, Li SY, Wang MY, Chang DY, Lu YS, Huang CS, Cheng AL, Lin CH, Chen PC. Environ Int. 2020 Sep;142:105850. doi: 10.1016/j.envint.2020.105850. Epub 2020 Jun 21.
  53. Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). Harbeck N, Franke F, Villanueva-Vazquez R, Lu YS, Tripathy D, Chow L, Babu GK, Im YH, Chandiwana D, Gaur A, Lanoue B, Rodriguez-Lorenc K, Bardia A. Ther Adv Med Oncol. 2020 Jul 26;12:1758835920943065.
  54. A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer. Lu YS, Lee KS, Chao TY, Tseng LM, Chitapanarux I, Chen SC, Liu CT, Sohn J, Kim JH, Chang YC, Yang Y, Shotelersuk K, Jung KH, Valenti R, Slader C, Gao M, Park YH. Clin Cancer Res. 2021 Jan 15;27(2):408-417.
  55. Phase Ib Study of Ribociclib Plus Fulvestrant and Ribociclib Plus Fulvestrant Plus PI3K-Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer. Tolaney SM, Im YH, Calvo E, Lu YS, Hamilton EP, Forero-Torres A, Bachelot T, Maur M, Fasolo A, Tiedt R, Nardi L, Stammberger U, Abdelhady AM, Ruan S, Lee SC. Clin Cancer Res. 2021 Jan 15;27(2):418-428.
  56. Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival. Chen TW, Jan IS, Chang DY, Lin CH, Chen IC, Chen HM, Cheng AL, Lu YS. J Neurooncol. 2020 May;148(1):165-172.
  57. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Park YH, Senkus-Konefka E, Im SA, Pentheroudakis G, Saji S, Gupta S, Iwata H, Mastura MY, Dent R, Lu YS, Yin Y, Smruti BK, Toyama T, Malwinder S, Lee SC, Tseng LM, Kim JH, Kim TY, Suh KJ, Cardoso F, Yoshino T, Douillard JY. Ann Oncol.  2020 Apr;31(4):451-469.
  58. Mortality of Pregnancy Following Breast Cancer Diagnoses in Taiwanese Women. Chuang SC, Lin CH, Lu YS, Hsiung CA. Oncologist. 2020 Feb;25(2):e252-e258.
  59. Ribociclib and Endocrine Therapy in Breast Cancer. Reply. Im SA, Lu YS, Tripathy D. N Engl J Med. 2019 Oct 17;381(16):1592-1593.
  60. Response to Sung, Rosenberg, and Yang. Lin CH, Yap YS, Lee KH, Yeo W, Ueno T, Li H, Huang SM, Lu YS*. J Natl Cancer Inst. 2019 Sep 23. pii: djz191. doi: 10.1093/jnci/djz191. [Epub ahead of print] *Correspondence
  61. Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian versus Western Populations. Chen CH, Lu YS, Cheng AL, Huang CS, Kuo WH, Wang MY, Chao M, Chen IC, Kuo CW, Lu TP, Lin CH. Oncologist. 2020 Jan;25(1):e16-e23
  62. Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models. Kuo CT, Chen CL, Li CC, Huang GS, Ma WY, Hsu WF, Lin CH, Lu YS*, Wo AM. Sci Rep. 2019 Jul 29;9(1):10898. *Co-Correspondence
  63. Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Yeo W, Ueno T, Lin CH, Liu Q, Lee KH, Leung R, Naito Y, Park YH, Im SA, Li H, Yap YS, Lu YS*; Asian Breast Cancer Cooperative Group. Breast Cancer Res Treat. 2019 Oct;177(3):549-559. *Correspondence
  64. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. Im SA, Lu YS*, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D. N Engl J Med. 2019 Jul 25;381(4):307-316. *Co-First author
  65. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. Iwata H, Masuda N, Kim SB, Inoue K, Rai Y, Fujita T, Chiu J, Ohtani S, Takahashi M, Miyaki T, Lu YS, Xu B, Yap YS, Bustam A, Yao B, Zhang B, Bryce R, Chan A. Future Oncol. 2019 Jul;15(21):2489-2501.
  66. Insights Into Breast Cancer in the East vs the West: A Review. Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC. JAMA Oncol. 2019 Oct 1;5(10):1489-1496.
  67. Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians versus the US Population. Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, Ueno T, Kwong A, Li H, Huang SM, Leung R, Han W, Tan B, Hu FC, Huang CS, Cheng AL, Lu YS*. J Natl Cancer Inst. 2019 Dec 1;111(12):1298-1306.. *Corresponding author
  68. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. N Engl J Med. 2019 May 16;380(20):1929-1940.  
  69. PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study. Yang MH, Chen IC, Lu YS*. J Formos Med Assoc. 2019 Sep;118(9):1333-1338.. *Corresponding author
  70. Association of pregnancy and mortality in women diagnosed with breast cancer: A Nationwide Population Based Study in Taiwan. Chuang SC, Lin CH, Lu YS, Hsiung CA. Int J Cancer. 2018 Nov 15;143(10):2416-2424.
  71. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS*. Lancet Oncol. 2018 Jul;19(7):904-915. *Corresponding author
  72. Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer. Chen BB, Lu YS, Yu CW, Lin CH, Chen TW, Wei SY, Cheng AL, Shih TT. Eur Radiol. 2018 Nov;28(11):4860-4870.
  73. Effect of glucocorticoid use on survival in patients with stage I-III breast cancer. Lin CH, Chuang PY, You SL, Chiang CJ, Huang CS, Wang MY, Chao M, Lu YS, Cheng AL, Tang CH. Breast Cancer Res Treat. 2018 Aug;171(1):225-234
  74. Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS. Chiu HH, Liao HW, Shao YY, Lu YS, Lin CH, Tsai IL, Kuo CH. Anal Chim Acta. 2018 Aug 17;1019:93-102.
  75. The breast graded prognostic assessment is associated with the survival outcomes in breast cancer patients receiving whole brain re-irradiation. Lai SF, Chen YH, Liang TH, Hsu CY, Lien HC, Lu YS, Huang CS, Kuo SH. J Neurooncol. 2018 Jul;138(3):637-647
  76. A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer. Chen TW, Yeh DC, Chao TY, Lin CH, Chow LW, Chang DY, Hsieh YY, Huang SM, Cheng AL, Lu YS*. Jpn J Clin Oncol. Jpn J Clin Oncol. 2018 Mar 1;48(3):242-247. *Corresponding author
  77. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Collaborators (592) …., Lu YS,….. Lancet Oncol. 2017 Dec;18(12):1688-1700.
  78. Adiposity, Inflammation and Breast Cancer Pathogenesis in Asian Women. Iyengar NM, Chen IC, Zhou XK, Giri DD, Falcone DJ, Winston LA, Wang H, Williams S, Lu YS, Hsueh TH, Cheng AL, Hudis CA, Lin CH, Dannenberg AJ. Cancer Prev Res (Phila). 2018 Apr;11(4):227-236.
  79. Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma. Chiu HH, Tsai IL, Lu YS, Lin CH, Kuo CH. Anal Bioanal Chem. 2017 Nov;409(28):6583-6593.
  80. PI-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen. Chen IC, Hsiao LP, Huang IW, Yu HC, Yeh LC, Lin CH, Wei-Wu Chen T, Cheng AL, Lu YS*. Sci Rep. 2017 Aug 29;7(1):9842. *Corresponding author
  81. Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients. Chow LW, Biganzoli L, Leo AD, Kuroi K, Han HS, Patel J, Huang CS, Lu YS, Zhu L, Chow CY, Loo WT, Glück S, Toi M. Asia Pac J Clin Oncol. 2017 Dec;13(6):372-378.
  82. Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1-2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy. Lai SF, Chen YH, Kuo WH, Lien HC, Wang MY, Lu YS, Lo C, Kuo SH, Cheng AL, Huang CS. Ann Surg Oncol. 2016 Nov;23(12):3860-3869
  83. A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer. Chen BB, Lu YS*, Lin CH, Chen WW, Wu PF, Hsu CY, Yu CW, Wei SY, Cheng AL, Shih TT. BMC Cancer. 2016 Jul 13;16:466. *Co-first author.
  84. Love RR, Hossain SM, Hussain MM, Mostafa MG, Laudico AV, Siguan SS, Adebamowo C, Sun JZ, Fei F, Shao ZM, Liu Y, Akram Hussain SM, Zhang B, Cheng L, Panigaro S, Walta F, Chuan JH, Mirasol-Lumague MR, Yip CH, Navarro NS Jr, Huang CS, Lu YS, Ferdousy T, Salim R, Akhter C, Nahar S, Uy G, Young GS, Hade EM, Jarjoura D. Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer. Eur J Cancer. 2016 Jun;60:107-16.
  85. Chen IC, Chang YC, Lu YS, Chung KP, Huang CS, Lu TP, Kuo WH, Wang MY, Kuo KT, Wu PF, Hsueh TH, Shen CY, Lin CH, Cheng AL. Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer. Sci Rep. 2016 Feb 15;6:21374.
  86. Lin PH, Kuo WH, Huang AC, Lu YS, Lin CH, Kuo SH, Wang MY, Liu CY, Cheng FT, Yeh MH, Li HY, Yang YH, Hsu YH, Fan SC, Li LY, Yu SL, Chang KJ, Chen PL, Ni YH, Huang CS. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer. Oncotarget. 2016 Feb 16;7(7):8310-20.
  87. Lin CH, Chen IC, Huang CS, Hu FC, Kuo WH, Kuo KT, Wang CC, Wu PF, Chang DY, Wang MY, Chang CH, Chen WW, Lu YS,* Cheng AL, TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays, Sci Rep. 2015 Dec 16;5:17879. * Co-correspondence
  88. Wu PF, Lin CH, Kuo CH, Chen WW, Yeh DC, Liao HW, Huang SM, Cheng AL, Lu YS.* A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis. BMC Cancer. 2015 Apr 17;15(1):299. * Correspondence
  89. Chuang SC, Wu GJ, Lu YS, Lin CH, Hsiung CA. Associations between Medical Conditions and Breast Cancer Risk in Asians: A Nationwide Population-Based Study in Taiwan. PLoS One. 2015 Nov 25;10(11):e0143410. 
  90. Lin CH, Shen CY, Lee JH, Huang CS, Yang CH, Kuo WH, Chang DY, Hsiung CN, Kuo KT, Chen WW, Chen IC, Wu PF, Kuo SH, Chen CJ, Lu YS*, Cheng AL. High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country. PLoS One. 2015 Apr 24;10(4):e0124908. * Co-correspondence
  91. Chen IC, Lin CH, Jan IS, Cheng AL, Lu YS*. Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis. J Formos Med Assoc. 2015 Apr 15. ;115(4):243-8.* Correspondence
  92. Wu LA, Chang RF, Huang CS, Lu YS, Chen HH, Chen JY, Chang YC. Evaluation of the treatment response to neoadjuvant chemotherapy in locally advanced breast cancer using combined magnetic resonance vascular maps and apparent diffusion coefficient. J Magn Reson Imaging. 2015 Apr 15.
  93. Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, Rau KM, Chen BB, Chao TC, Huang SM, Huang CS, Shih TT, Cheng AL; Taiwan Breast Cancer Consortium. Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. Clin Cancer Res. 2015 Apr 15;21(8):1851-8.
  94. Chen TW, Chen HM, Lin CH, Huang CS, Cheng AL, Lai MS, Lu YS*. No increased venous thromboembolism risk in Asian breast cancer patients receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2014 Nov;148(1):135-42. *Corresponding author
  95. Lin CH, Chuang PY, Chiang CJ, Lu YS, Cheng AL, Kuo WH, Huang CS, Lai MS, You SL, Tang CH. Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cancer registry-based study. Oncologist. 2014 Jun;19(6):583-91.
  96. Lin CC, Su WC, Yen CJ, Hsu CH, Su WP, Yeh KH, Lu YS, Cheng AL, Huang DC, Fritsch H, Voss F, Taube T, Yang JC. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer. 2014 May 13;110(10):2434-40.
  97. Lien HC, Lee YH, Jeng YM, Lin CH, Lu YS, Yao YT. Differential expression of hyaluronan synthase 2 in breast carcinoma and its biological significance. Histopathology. 2014 Feb 15 [Epub ahead of print]
  98. Kuo SH, Yang SY, Lien HC, Lo C, Lin CH, Lu YS, Cheng AL, Chang KJ, Huang CS. CYP19 genetic polymorphism haplotype AASA is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancer. Biomed Res Int. 2013;2013:562197
  99. Chen WW, Chang DY, Huang SM, Lin CH, Hsu C, Lin MH, Huang CS, Lu YS*, Cheng AL. The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines. Breast. 2013 Dec;22(6):1148-54. *Corresponding author
  100. Wu PF, Huang WC, Yang JC, Lu YS, Shih JY, Wu SG, Lin CH, Cheng AL. Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas. J Neurooncol. 2013 Oct;115(1):61-70.
  101. Lien HC, Wang CC, Lin CH, Lu YS, Huang CS, Hsiao LP, Yao YT. Differential expression of ubiquitin carboxy-terminal hydrolase L1 in breast carcinoma and its biological significance. Hum Pathol. 2013 Sep;44(9):1838-48.
  102. Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH, Chang DY, Li H, Lin YC, Chang HK, Chao TC, Ouyang F, Hou MF. Distant metastasis in triple-negative breast cancer. Neoplasma. 2013;60(3):290-4.
  103. Lin CH, Liu JM, Lu YS, Lan C, Lee WC, Kuo KT, Wang CC, Chang DY, Huang CS, Cheng AL. Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation. J Clin Pathol. 2013 Feb;66(2):140-5.
  104. Kuo YH, Lin CH, Shau WY, Chen TJ, Yang SH, Huang SM, Hsu C, Lu YS*, Cheng AL. Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy. BMC Cancer. 2012 Dec 26;12(1):620. *Corresponding author
  105. Liang YH, Wu PF, Lin CH, Lu YS*. Hashimoto’s encephalopathy as the cause of deteriorating consciousness during treatment of leptomeningeal carcinomatosis from breast cancer. J Clin Oncol. 2012 Nov 20;30(33):e358-9.  *Corresponding author
  106. Wang CC, Liau JY, Lu YS, Chen JW, Yao YT, Lien HC. Differential expression of moesin in breast cancers and its implication in epithelial-mesenchymal transition. Histopathology. 2012 Jul;61(1):78-87.
  107. Chen WW, Shao YY, Shau WY, Lin ZZ, Lu YS, Chen HM, Kuo RN, Cheng AL, Lai MS. The impact of Diabetes Mellitus on prognosis of early breast cancer in Asia. Oncologist. 2012;17(4):485-91.
  108. Lu YS, Chou CH, Tzen KY, Gao M, Cheng AL, Kulp SK, Cheng JC. Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e181-9.
  109. Lin CH, Chen YC, Chiang CJ, Lu YS, Kuo KT, Huang CS, Cheng WF, Lai MS, You SL, Cheng AL. The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. Int J Cancer. 2012 Jun 1;130(11):2629-37.   
  110. Shao YY, Lin ZZ, Hsu C, Lee KD, Hsiao CH, Lu YS, Huang CC, Shen YC, Hsu CH, Cheng AL. Efficacy, safety, and potential biomarkers of Thalidomide plus Metronomic chemotherapy for advanced hepatocellular carcinoma. Oncology. 2012;82(1):59-66. Epub 2012 Feb 4. 
  111. Kuo WH, Lin PH, Huang AC, Chien YH, Liu TP, Lu YS, Bai LY, Sargeant AM, Lin CH, Cheng AL, Hsieh FJ, Hwu WL, Chang KJ. Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer. J Hum Genet. 2012 Feb;57(2):130-8. doi: 10.1038/jhg.2011.142. Epub 2012 Jan
  112. Chen IC, Lin CH, Huang CS, Lien HC, Hsu C, Kuo WH, Lu YS*, Cheng AL. Lack of efficacy of systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Res Treat. 2011 Nov;130(1):345-51. *Corresponding author
  113. Lin CH, Lu YS, Huang CS, Kuo KT, Wang CC, You SL, Lin PH, Chang DY, Kuo WH, Chang KJ, Cheng AL. Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients? J Clin Pathol. 2011 Sep;64(9):781-7.
  114. Chen IC, Lin CH, Lu YS. Axillary vs sentinel lymph node dissection for invasive breast cancer. JAMA. 2011 Jun 8;305(22):2288-9; author reply 2290-1.  
  115. Lu YS, Chen DR, Tseng LM, Yeh DC, Chen ST, Hsieh CM, Wang HC, Yeh HT, Kuo SH, Huang CS. Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer. Cancer Chemotherapy and Pharmacology. 2011 Jun;67(6):1257-63.
  116. Yeh PY, Lu YS, Ou DL, Cheng AL. IkappaB kinases increase Myc protein stability and enhance progression of breast cancer cells. Molecular Cancer 2011, May 16;10:53.  
  117. Lin PH, Chiu CF, Lu YS*. Cisplatin as an active treatment in zoledronate-refractory hypercalcemia. Ann Oncol. 2011 May;22(5):1244-6. *Corresponding author  
  118. Kuo SH, Hsu CH, Chen LT, Lu YS, Lin CH, Yeh PY, Jeng HJ, Gao M, Yeh KH, Cheng AL. Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001. Eur J Cancer. 2011 Feb 17.
  119. Wang J, Shih TT, Yen RF, Lu YS, Chen CY, Mao TL, Lin CH, Kuo WH, Tsai YS, Chang KJ, Chien KL. The association of infrared imaging findings of the breast with hormone receptor and human epidermal growth factor receptor 2 status of breast cancer. Acad Radiol. 2011 Feb;18(2):212-9.
  120. Chiang CT, Yeh PY, Gao M, Chen CW, Yeh LC, Feng WC, Kuo SH, Hsu CH, Lu YS*, Cheng AL. Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma. Cancer Letter. 2010 Dec 8;298(2):195-203.  *Corresponding author
  121. Tan YO, H Sehwan, Lu YS, Yip CH Yip, Sunpaweravong P, Jeong J, Caguioa PB, Aggarwal S, Yeoh EM, Moon H. The prevalence and assessment of ErbB2-positive breast cancer in Asia: A literature survey. Cancer. 2010 Dec 1;116(23):5348-57.
  122. Vogel C, Chan A, Gril B, Kim SB, Kurebayashi J, Liu L, Lu YS, Moon H. Jap. Management of ErbB2-positive breast cancer – insights from preclinical and clinical studies with lapatinib. J J Clin. Oncol. 2010 Nov;40(11):999-1013.
  123. Lin PH, Lu YS, Lin CH, Chang DY, Huang CS, Cheng AL, Yeh KH. Vinorelbine plus 24-hour infusion of high-dose 5-fluorouracil and leucovorin as effective palliative chemotherapy for breast cancer patients with acute disseminated intravascular coagulation. Anticancer Research 2010 Jul;30(7):3087-91.
  124. Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C, Kuo WH, Chang KJ, Lin CH, Cheng AL. Predictive and prognostic values of Tau and ERCC1 in advanced breast cancer patients treated with Paclitaxel and Cisplatin. Jpn J Clin Oncol. 2010 Apr;40(4):286-93.
  125. Huang CS, Lin CH, Lu YS, Shen CY. Unique features of breast cancer in Asian women-Breast cancer in Taiwan as an example. J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):300-3.
  126. Lin CH, Lien HC, Hu FC, Lu YS, Kuo SH, Wu LC, You SL, Cheng AL, Chang KJ, Huang CS. Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. J Zhejiang Univ Sci B. 2010 Jan;11(1):1-9.
  127. Chang DY, Lin CH, Lu YS. Locoregional therapy improves survival for metastatic breast cancer patients? Benefit remains questionable! J Clin Oncol. 2009 Nov 1;27(31):e179.
  128. Wong NS, Anderson BO, Khoo KS, Ang PT, Yip CH, Lu YS, Voravud N, Shao ZM, Pritchard KI; Asian Oncology Summit. Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009 Nov;10(11):1077-85.
  129. Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL. Induction of bim expression contributes to the antitumor synergy between Sorafenib and Mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. Clin Cancer Res. 2009 Sep 8. 15(18):5820-8.
  130. Wu PF, Kuo KT, Kuo LT, Lin YT, Lee WC, Lu YS, Yang CH, Wu RM, Tu YK, Tasi JC, Tseng HM, Tseng SH, Cheng AL, Lin CH. O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Lung Cancer. 2009 Sep 7.
  131. Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, Shen YC, Kuo SH, Lan C, Liu JM, Kuo WH, Chang KJ, Cheng AL. Molecular subtypes of breast cancer emerging in young women in Taiwan: Evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiology, Biomarkers & Prevention. 2009 Jun;18(6):1807-14. 
  132. Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, Chen PJ, Cheng AL. Bortezomib overcomes TRAIL resistance in hepatocellular carcinoma cells in part through the inhibition of PI3K/Akt pathway. J. Biol Chem 2009 April 24;284(17):11121-33.
  133. Gao M, Yeh PY, Lu YS, Hsu CH, Chen KF, Lee WC, Feng WC, Chen CS, Kuo ML, Cheng AL. OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma. Cancer Res 2008 Nov 15;68(22):9348-57.
  134. Gao M, Yeh PY, Lu YS, Chang WC, Kuo ML, Cheng AL. NF-kappaB p50 promotes tumor cell invasion through negative regulation of invasion suppressor gene CRMP-1 in human lung adenocarcinoma cells. Biochem Biophys Res Commun. 2008 Nov 14;376(2):283-7.
  135. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2008 Aug 15;68(16):6698-707.
  136. Kuo SH, Lien HC, You SL, Lu YS, Lin CH, Chen TZ, Huang CS. Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients. Breast. 2008 Dec;17(6):646-53. Epub 2008 Jul 1.
  137. Huang CS, Kuo SH, Lien HC, Yang SY, You SL, Shen CY, Lin CH, Lu YS, Chang KJ. The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers. Oncologist. 2008;13:751-60.
  138. Lien HC, Lu YS, Shun CT, Yao YT, Chang WC, Cheng AL. Differential expression of glucocorticoid receptor in carcinomas of the human digestive system. Histopathology 2008 Feb;46(4):1119-30.
  139. Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, Kulp SK, Muthusamy N, Byrd JC, Cheng AL, Chen CS. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein Kinase C Delta signaling. Cancer Research. 2008;68:1204-12.
  140. Shih IL, Lu YS, Wang HP, Liu KL. Pneumatosis coli after etoposide chemotherapy for breast cancer. J Clin Oncol. 2007 Apr 20;25(12):1623-5.
  141. Lu YS, Kashida Y, Kulp SK, Wang YC, Hung JH, Tang M, Lin ZZ, Chen TJ,  Cheng AL, Chen CS. Efficacy of OSU-HDAC42, a novel histone deacetylase inhibitor, in murine models of hepatocellular carcinoma. Hepatology. 2007 Oct;46(4):1119-30.   
  142. Lin CC, Cheng AL, Hsu CH, Lu YS, Hsu C, Yeh KH, Wu CY, Huang CS, Yang CH. A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer. Anticancer Res. 2007;27(1B):641-5.
  143. Lu YS, Lien HC, Yeh PY, Kuo SH, Chang WC, Kuo ML, Cheng AL. Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity. Lung Cancer. 2006 Sep;53(3):303-10. 
  144. Lien HC, Lu YS, Cheng AL, Chang WC, Jeng YM, Kuo YH, Huang CS, Chang KJ, Yao YT. Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms. J Pathol. 2006 Jul;209(3):317-27.
  145. Ch’ang HJ, Wang CC, Cheng AL, Hsu C, Lu YS, Chang MC, Lin JT, Wang HP, Shiah HS, Liu TW, Chang JY, Whang-Peng J, Chen LT. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer. J Gastroenterol Hepatol. 2006 May;21(5):874-9.
  146. Lu YS, Yeh PY, Chuang SE, Gao M, Kuo ML, Cheng AL.Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-{kappa}B activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa. J Endocrinol. 2006 Feb;188(2):311-9.
  147. Lu YS, Lien HC, Yeh PY, Yeh KH, Kuo ML, Kuo SH, Cheng AL. Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors. World J Gastroenterol. 2005 Oct 28;11(40):6373-80.
  148. Su WP, Wen CC, Hsiung CA, Su IJ, Cheng AL, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu C, Hsu CH, Lu YS, Tien HF, Chao TY, Chen LT, Whang-Peng J, Chen PJ. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World J Gastroenterol. 2005 Sep 14;11(34):5283-8.
  149. Yeh KH, Lu YS, Hsu CH, Lin JF, Hsu C, Kuo SH, Li SJ, Cheng AL. Phase II study of weekly Paclitaxel and 24-Hour infusion of high-Dose 5-Fluorouracil and Leucovorin in the treatment of recurrent or metastatic gastric cancer. Oncology 2005 ;69(1):88-95.
  150. Yeh KH, Lu YS, Hsu CH, Lin JF, Chao HJ, Huang TC, Chung CY, Chang CS, Yang CH, Cheng AL. Phase II study of weekly Vinorelbine and 24-hour infusion of high-dose 5-Fluorouracil plus Leucovorin as first-line treatment of advanced breast cancer. British Journal of Cancer. 2005;92:1013-18.
  151. Chang YC, Huang CS, Liu YJ, Chen JH, Lu YS, Tseng WYI. Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI. Phys. Med. Biol. 2004;49:3593-602.
  152. Lu YS, Hsu C, Li CC, Kuo SH, Yeh KH, Yang CH, Hsu CH, Wu CY, Cheng AL. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma. Hepato-Gastroenterology. 2004;51(57):815-9.
  153. Lu YS, Kuo SH, Huang CS. Recent advances in the management of primary breast cancers. J Formos Med Assoc. 2004;103(8):579-98.
  154. Hsu C, Shen YC, Yang CH, Yeh KH, Lu YS, Hsu CH, Liu HT, Li CC, Chen JS, Wu CY, Cheng AL. Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. British Journal of Cancer. 2004;90(9):1715-9.
  155. Yeh KH, Lu YS, Hsiao CH, Cheng AL. High-dose tamoxifen modulates drug resistance to doxorubicin, dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma. Anticancer Research. 2003;23(6D):5133-7.
  156. CH Hsu, AL Cheng, C Hsu, CH Yang, YS Lu, CC Lin, CF Bu, KH Yeh. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-f;uorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer – improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil. Anticancer Research. 2002;22:3621-28.
  157. Hsu C, Huang CS, Chao TY, Lu YS, Bu CF, Chen MM, Cheng AL. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast cancer. Cancer 2002;95(10):2044-50.
  158. Chung SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M, Cheng AL. Basal levels and patterns of anticancer drug-induced activation of NF-kB, and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochemical Pharmacology. 2002;63(9):1709-16.
  159. Chen HS, Yen TS, Lu YS, Yang JC, Ko YL. Transient ‘milky urine’ after cardiac catheterization: another unreported cause of non-parasitic chyluria [letter]. Nephron. 1996;72(2):367-8.

BOOKS

Sargen A, Lu YS, Cheng AL, Cheng CS. Chapter 12, Histone Deacetylase Inhibitors in Cancer Therapy. Cancer Epigenetics ed 1. Taylor & Francis, 2008.